Burden of Disease of Breast Cancer in Italy: A Real-World Data Analysis.

Autor: Mennini FS; Economic Evaluation and HTA (EEHTA-CEIS), Faculty of Economics, University of Rome 'Tor Vergata', Rome, Italy.; Department of Accounting and Finance at Kingston University, London, UK., Marcellusi A; Economic Evaluation and HTA (EEHTA-CEIS), Faculty of Economics, University of Rome 'Tor Vergata', Rome, Italy., Sciattella P; Economic Evaluation and HTA (EEHTA-CEIS), Faculty of Economics, University of Rome 'Tor Vergata', Rome, Italy., Scortichini M; Economic Evaluation and HTA (EEHTA-CEIS), Faculty of Economics, University of Rome 'Tor Vergata', Rome, Italy., Ragonese A; Economic Evaluation and HTA (EEHTA-CEIS), Faculty of Economics, University of Rome 'Tor Vergata', Rome, Italy. angelaragonese@gmail.com., Cattel F; Direttore della Farmacia Ospedaliera della Azienda Ospedaliero-Universitaria della Città della Salute e della Scienza di Torino, Turin, Italy., D'Antona R; Europa Donna Italia, Milan, Italy., Del Mastro L; IRCCS Ospedale Policlinico San Martino Università degli Studi di Genova, Genoa, Italy., Gori S; Oncologico IRCCS Ospedale Sacro Cuore Don Calabria, Negrar di Valpolicella, Verona, Italy., Perrone G; Facoltà Dipartimentale di Medicina e Chirurgia, Università Campus Bio-Medico di Roma, Rome, Italy., Migliorini R; Coordinamento Generale Medico-Legale, Istituto Nazionale di Previdenza Sociale (INPS), Rome, Italy., Trabucco Aurilio M; Dipartimento di Medicina e Scienze Sanitarie, Università del Molise, Campobasso, Italy.
Jazyk: angličtina
Zdroj: PharmacoEconomics - open [Pharmacoecon Open] 2024 Nov 23. Date of Electronic Publication: 2024 Nov 23.
DOI: 10.1007/s41669-024-00543-1
Abstrakt: Background: Breast cancer (BC) constitutes a significant public health challenge in Italy, with a considerable impact on healthcare resources and societal costs. Despite advancements in diagnostics and therapies, the economic burden of BC remains substantial, necessitating a comprehensive evaluation to inform healthcare policy and resource allocation. The aim of this study is to estimate both direct health costs and social security costs related to BC.
Methods: This study utilized real-world data from the Italian Health Information System (HIS) and Local Health Unit (LHU) Umbria 2 HIS databases spanning 2010-2019. Direct health costs, encompassing hospitalizations, outpatient visits, and drug prescriptions, were assessed alongside social security costs associated with BC-related work inability. Statistical analyses and probabilistic models were employed to estimate costs and evaluate trends over time.
Results: The analysis revealed an annual cost of €273 million for hospital admissions related to BC in Italy, with metastatic BC (MBC) incurring the highest average annual cost per patient (€5018). When outpatient visits and drug consumption were incorporated, the mean annual cost per patient in LHU Umbria 2 rose to €11,380 for MBC. Social security costs, predominantly comprising disability benefits (DBs), totaled €579 million annually. Overall, the study estimated the total annual economic impact of BC in Italy to exceed €1 billion, with social costs representing 50.4% of the total burden.
Conclusions: This comprehensive assessment underscores the substantial economic strain imposed by BC in Italy and highlights the need for early detection and intervention strategies to mitigate costs and enhance patient outcomes. These findings offer valuable insights into the economic landscape of BC, guiding policy decisions and resource allocation efforts aimed at optimizing BC management and alleviating its societal burden.
Competing Interests: Declarations. Funding: The study was funded by Daiichi sankyo. Role of the funder/sponsor: The funder had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. Conflicts of interest: The authors have no relevant financial or non-financial interests to disclose. Availability of data and material: The datasets generated during and/or analyzed during the current study are available from the corresponding author upon reasonable request. Ethics approval: Not applicable. Consent to participate: Not applicable. Consent for publication: Not applicable. Code availability: The code is available from the corresponding author upon reasonable request. Author contributions: All authors contributed to the study conception. A.M., P.S., and F.S.M. developed the study design; P.S. and M.S. conducted the statistical analysis, derived the analytical results, and wrote the first draft of the manuscript. All authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.
(© 2024. The Author(s).)
Databáze: MEDLINE
Externí odkaz: